The curative potential of cancer chemotherapy in Burkitt's lymphoma was first identified by Burkitt and Clifford in treating endemic cases in East Africa. Subsequent to the recognition of Burkitt's lymphoma as a histologic entity, a number of cases were identified as occurring sporadically throughout the world. Treatment of such patients, however, did not seem to yield satisfactory results, and a widespread impression developed that patients with nonendemic Burkitt's lymphoma did not respond as well as did patients in Africa. Some reasons for this pessimism in the management of nonendemic Burkitt's lymphoma include the lack of a uniform treatment approach and the fact that most large institutions encountered only one or two cases annually.
The Pediatric Oncology Branch of the National Cancer Institute has recently published1 the results of 54 patients with American Burkitt's lymphoma who were treated on uniform protocols involving chemotherapy and radiotherapy. Thirty-three patients were treated collaboratively